Scpx- Scorpius Holdings Inc. (SCPX)

$0.83

-0.02

(-1.83%)▲

Market is closed - opens 7 PM, 13 Sep 2024

Performance

  • $0.79
    $0.89
    $0.83
    downward going graph

    5.01%

    Downside

    Day's Volatility :11.42%

    Upside

    6.74%

    downward going graph
  • $0.73
    $106.00
    $0.83
    downward going graph

    11.93%

    Downside

    52 Weeks Volatility :99.31%

    Upside

    99.22%

    downward going graph

Returns

PeriodScpx- Scorpius Holdings Inc.Index (Russel 2000)
3 Months
-95.72%
0.0%
6 Months
-97.36%
0.0%
1 Year
35.33%
0.0%
3 Years
-65.56%
-21.1%

Highlights

Market Capitalization
2.6M
Book Value
$51.92
Earnings Per Share (EPS)
-11440.72
Wall Street Target Price
10.0
Profit Margin
0.0%
Operating Margin TTM
-1144.6%
Return On Assets TTM
-32.04%
Return On Equity TTM
-91.85%
Revenue TTM
9.8M
Revenue Per Share TTM
53.89
Quarterly Revenue Growth YOY
15.5%
Gross Profit TTM
-16.7M
EBITDA
-25.0M
Diluted Eps TTM
-11440.72
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Sell
    0
    0%Buy
    50%Hold
    50%Sell
Based on 6 Wall street analysts offering stock ratings for Scpx- Scorpius Holdings Inc.(by analysts ranked 0 to 5 stars)
Based on 6 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
00
Hold
3
3
3
Sell
3
3
3

Analyst Forecast

What analysts predicted

Upside of 1104.82%

Current $0.83
Target $10.00

Company Financials

FY21Y/Y Change
Revenue
2.1M
↑ 0.0%
Net Income
-35.1M
↑ 0.0%
Net Profit Margin
-1.7K%
↑ 0.0%
FY21Y/Y Change
Revenue
2.1M
↑ 0.0%
Net Income
-35.1M
↑ 0.0%
Net Profit Margin
-1.7K%
↑ 0.0%
FY22Y/Y Change
Revenue
6.0M
↑ 0.0%
Net Income
-43.4M
↑ 0.0%
Net Profit Margin
-726.21%
↑ 0.0%
FY22Y/Y Change
Revenue
6.0M
↑ 0.0%
Net Income
-43.4M
↑ 0.0%
Net Profit Margin
-726.21%
↑ 0.0%
FY23Y/Y Change
Revenue
7.0M
↑ 0.0%
Net Income
-45.2M
↑ 0.0%
Net Profit Margin
-646.44%
↑ 0.0%
FY23Y/Y Change
Revenue
7.0M
↑ 0.0%
Net Income
-45.2M
↑ 0.0%
Net Profit Margin
-646.44%
↑ 0.0%
Q1 FY23Q/Q Change
Revenue
765.9K
↑ 858.37%
Net Income
-12.8M
↑ 5.21%
Net Profit Margin
-1.7K%
↑ 13535.9%
Q2 FY23Q/Q Change
Revenue
657.8K
↓ 14.12%
Net Income
-13.9M
↑ 8.66%
Net Profit Margin
-2.1K%
↓ 442.73%
Q3 FY23Q/Q Change
Revenue
723.1K
↑ 9.93%
Net Income
-13.1M
↓ 5.47%
Net Profit Margin
-1.8K%
↑ 295.89%
Q4 FY23Q/Q Change
Revenue
4.8M
↑ 570.43%
Net Income
-5.4M
↓ 58.82%
Net Profit Margin
-111.55%
↑ 1704.52%
Q1 FY24Q/Q Change
Revenue
3.5M
↓ 27.52%
Net Income
-4.4M
↓ 18.32%
Net Profit Margin
-125.71%
↓ 14.16%
Q2 FY24Q/Q Change
Revenue
759.9K
↓ 78.37%
Net Income
-8.9M
↑ 100.9%
Net Profit Margin
-1.2K%
↓ 1042.12%
FY21Y/Y Change
Total Assets
121.0M
↑ 0.0%
Total Liabilities
8.9M
↑ 0.0%
FY21Y/Y Change
Total Assets
121.0M
↑ 0.0%
Total Liabilities
8.9M
↑ 0.0%
FY22Y/Y Change
Total Assets
104.4M
↑ 0.0%
Total Liabilities
32.0M
↑ 0.0%
FY22Y/Y Change
Total Assets
104.4M
↑ 0.0%
Total Liabilities
32.0M
↑ 0.0%
FY23Y/Y Change
Total Assets
51.0M
↑ 0.0%
Total Liabilities
22.7M
↑ 0.0%
FY23Y/Y Change
Total Assets
51.0M
↑ 0.0%
Total Liabilities
22.7M
↑ 0.0%
Q1 FY23Q/Q Change
Total Assets
91.5M
↓ 34.97%
Total Liabilities
31.2M
↓ 54.34%
Q2 FY23Q/Q Change
Total Assets
80.2M
↓ 12.38%
Total Liabilities
33.1M
↑ 6.22%
Q3 FY23Q/Q Change
Total Assets
69.9M
↓ 12.81%
Total Liabilities
36.5M
↑ 10.12%
Q4 FY23Q/Q Change
Total Assets
51.0M
↓ 27.0%
Total Liabilities
22.7M
↓ 37.64%
Q1 FY24Q/Q Change
Total Assets
50.5M
↓ 1.05%
Total Liabilities
25.2M
↑ 11.0%
Q2 FY24Q/Q Change
Total Assets
46.7M
↓ 7.55%
Total Liabilities
24.8M
↓ 1.65%
FY21Y/Y Change
Operating Cash Flow
-38.1M
↑ 0.0%
Investing Cash Flow
9.8M
-
Financing Cash Flow
25.5M
↑ 0.0%
Q1 FY23Q/Q Change
Operating Cash Flow
-13.8M
↑ 76.61%
Investing Cash Flow
13.5M
↑ 0.0%
Financing Cash Flow
-298.5K
↓ 93.73%

Technicals Summary

Sell

Neutral

Buy

Scpx- Scorpius Holdings Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Scpx- Scorpius Holdings Inc.
Scpx- Scorpius Holdings Inc.
-11.0%
-97.36%
35.33%
-65.56%
-64.92%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
0.53%
20.61%
40.93%
82.08%
313.49%
Novo Nordisk A/s
Novo Nordisk A/s
2.31%
2.37%
41.89%
174.22%
452.16%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-2.2%
76.34%
35.57%
40.87%
212.74%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
2.37%
14.89%
38.0%
148.92%
173.61%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Scpx- Scorpius Holdings Inc.
Scpx- Scorpius Holdings Inc.
NA
NA
NA
0.0
-0.92
-0.32
NA
51.92
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
30.21
30.21
1.55
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
45.38
45.38
2.06
3.41
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.55
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.58
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Scpx- Scorpius Holdings Inc.
Scpx- Scorpius Holdings Inc.
Sell
$2.6M
-64.92%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$125.3B
313.49%
30.21
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$576.2B
452.16%
45.38
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$33.6B
212.74%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$123.5B
173.61%
32.84
-4.74%

Insights on Scpx- Scorpius Holdings Inc.

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 4.84M → 759.94K (in $), with an average decrease of 53.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -4.41M → -8.87M (in $), with an average decrease of 100.9% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 41.9% return, outperforming this stock by 6.6%

Company Information

heat biologics is a clinical-stage company focused on developing its proprietary impact™ (immune pan-antigen cytotoxic therapy), a fully allogeneic (“off-the-shelf”) cell-based immunotherapy for use in the treatment of a wide range of cancers. heat's impact therapy is a first-in-class, fully human immunotherapy that functions as both an immune stimulator and an antigen-delivery system. impact effectively transforms living allogeneic cells into "osmotic pumps" that continuously secrete cancerous antigens to robustly stimulate the immune system against the targeted cancer. impact therapy is applicable to a wide range of cancers. heat is currently conducting two phase 2 clinical trials with its hs-110 to treat non-small cell lung cancer (nsclc) and its hs-410 to treat bladder cancer.

Organization
Scpx- Scorpius Holdings Inc.
Employees
82
CEO
Mr. Jeffrey Alan Wolf J.D.
Industry
Miscellaneous

Discover More

FAQs